Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to establish lay user performance criteria for the SavvyCheck Vaginal Yeast Test in comparison to standard vaginal yeast culture and identification method for Candida (the Reference Method). Polymerase chain reaction (PCR) and sequencing of fungi will be used as an aid to explain the nature of the discrepancy in the case of discordant results between the lay user-performed SavvyCheck Vaginal Yeast Test and standard vaginal yeast culture and identification method for Candida.


Clinical Trial Description

The purpose of this study is to establish lay user performance criteria for the SavvyCheck Vaginal Yeast Test in comparison to standard vaginal yeast culture and identification method for Candida (the Reference Method). Polymerase chain reaction (PCR) and sequencing of fungi will be used as an aid to explain the nature of the discrepancy in the case of discordant results between the lay user-performed SavvyCheck Vaginal Yeast Test and standard vaginal yeast culture and identification method for Candida. Primary Objective: The primary objective is to establish lay user performance criteria (sensitivity and specificity) of the SavvyCheck Vaginal Yeast Test in comparison to the Reference Method (vaginal Candida yeast culture) Secondary Objectives: 1. To determine the positive predictive value and negative predictive value of the lay user-performed SavvyCheck Vaginal Yeast Test in comparison to the Reference Method (vaginal Candida yeast culture) 2. To determine the concordance between the results determined by lay user-performed SavvyCheck Vaginal Yeast Test -vs. trained user-performed SavvyCheck Vaginal Yeast Test Exploratory Objectives: 1. To determine the concordance between the results determined by lay user-performed SavvyCheck Vaginal Yeast Test -vs. vaginal wet mount microscopy results 2. To determine the concordance between results determined by lay user-performed SavvyCheck Vaginal Yeast Test -vs. PCR and sequencing 3. To determine the concordance between results determined by the Reference Method (vaginal Candida yeast culture) -vs. PCR and sequencing Primary Endpoints: Calculation of sensitivity and specificity of the lay user-performed SavvyCheck Vaginal Yeast Test as compared to the Reference Method (vaginal Candida yeast culture) Secondary Endpoints: 1. Calculation of positive and negative predictive value of lay user-performed SavvyCheck Vaginal Yeast Test results as compared to the Reference Method (vaginal Candida yeast culture) 2. Calculation of concordance between the results determined by lay user-performed SavvyCheck Vaginal Yeast Test results -vs. trained user-performed SavvyCheck Vaginal Yeast Test results Exploratory Endpoints: 1. Calculation of concordance between the results determined by lay user-performed SavvyCheck Vaginal Yeast Test -vs. vaginal wet mount microscopy 2. Calculation of concordance between results determined by lay user-performed SavvyCheck Vaginal Yeast Test -vs. PCR and sequencing 3. Calculation of concordance between results determined by the Reference Method (vaginal Candida yeast culture) -vs. PCR and sequencing Women, aged 18 years and older, symptomatic and asymptomatic for vaginitis will be enrolled in the study. We estimate that it will require a total enrollment of up to 600 symptomatic women at all clinical sites combined, to achieve the target of at least n=216 Reference Method (vaginal Candida yeast culture) positives. In addition, a combined total of 320 asymptomatic women will be enrolled in the study from the four clinical sites combined, to achieve the target of at least n=170 Reference Method (vaginal Candida yeast culture) negatives. Three, large, regional, DoD military treatment facilities (MTFs) 1. Womack Army Medical Center (WAMC) at Fort Liberty; Fayetteville, NC 2. Landstuhl Regional Medical Center (LRMC); Landstuhl, Germany 3. Brooke Army Medical Center (BAMC); Fort Sam Houston, TX The SavvyCheck Vaginal Yeast Test is a lateral flow immunochromatographic qualitative test for the detection of Candida antigen in vaginal secretions sampled by a swab, as an aid for identification of vulvovaginal candidiasis as a primary cause of vaginal yeast infections. The SavvyCheck Vaginal Yeast Test is designed for use by women experiencing vaginal symptoms, including: increased vaginal discharge, vaginal itching, vaginal soreness and irritation, rash on the labia, and genital burning that may worsen during urination. The SavvyCheck Vaginal Yeast Test is indicated for over-the-counter use. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05079711
Study type Observational
Source Uniformed Services University of the Health Sciences
Contact Elizabeth A Kostas-Polston, PhD
Phone 301.295.1531
Email elizabeth.kostas-polston@usuhs.edu
Status Recruiting
Phase
Start date March 18, 2022
Completion date August 30, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT05012852 - Evaluation of VagiVitalAC for Treatment of Candida Vulvovaginitis N/A
Completed NCT02150655 - Study of the Microbiota, Metabolome, and Environmental Toxins in Relation to Reproductive Health in Rwandan Women Phase 0
Completed NCT00755053 - Comparative Efficacy of Ovule vs Tablet Phase 3
Completed NCT02679456 - Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis Phase 2
Completed NCT02242695 - Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis Phase 4
Recruiting NCT06397248 - DeVEnIR: Defining Vulvovaginal Candidiasis - Elements of Infection and Remedy
Completed NCT00895453 - Monthly Itraconazole Versus Classic Homeopathy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC) N/A
Completed NCT05327192 - VVC Sampling Study for Analysis Validation
Completed NCT05399641 - Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis Phase 3
Completed NCT01806623 - The Study Of Fluconazole For Vulvovaginal Candidiasis Phase 3
Completed NCT05507333 - Clinical Performance of the Gedea Pessary in Adult Women With Vulvovaginal Candidiasis N/A
Completed NCT01144286 - Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment Phase 2
Completed NCT00353561 - Diabetes Mellitus and Vulvovaginal Candidiasis Phase 3
Recruiting NCT05895162 - Zinc-containing Vaginal Gel and Oral Fluconazole for Vulvovaginal Candidiasis. N/A
Not yet recruiting NCT06450990 - Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection Phase 1/Phase 2
Recruiting NCT05908682 - Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes
Completed NCT02203942 - Comparing NAAT Testing to Standard Methods for the Diagnosis of Vaginitis N/A
Completed NCT01926028 - Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis Phase 1/Phase 2
Completed NCT00194324 - Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina Phase 4
Completed NCT02866227 - TOL-463 Phase 2 Study for Vaginitis Phase 2